NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
AbbVie
National Institutes of Health Clinical Center (CC)
Palleon Pharmaceuticals, Inc.
Masonic Cancer Center, University of Minnesota
pharmaand GmbH
Numab Therapeutics AG
Advaxis, Inc.
Exelixis
Pfizer
CytomX Therapeutics
Kaiser Permanente
Revolution Medicines, Inc.
Becton, Dickinson and Company
Advaxis, Inc.
Tesaro, Inc.
Pfizer
Institut Bergonié
PharmaMar
Northwestern University
Nektar Therapeutics
National Institutes of Health Clinical Center (CC)
Xoft, Inc.
Eli Lilly and Company
Pfizer
Imperial College London
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
Novartis
National Institutes of Health Clinical Center (CC)
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Pfizer
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Traws Pharma, Inc.
OHSU Knight Cancer Institute
Amgen
Mayo Clinic
University of Pittsburgh
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Sandoz
Xian-Janssen Pharmaceutical Ltd.
University of South Florida
Genentech, Inc.
GlaxoSmithKline
Eleison Pharmaceuticals LLC.
University of Utah